enGene (NASDAQ:ENGN) Releases Earnings Results, Misses Estimates By $0.11 EPS

enGene (NASDAQ:ENGN) announced its quarterly earnings data on Monday. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.11), Zacks reports.

enGene Stock Performance

Shares of NASDAQ ENGN traded down $0.01 during mid-day trading on Monday, hitting $5.24. The company had a trading volume of 27,537 shares, compared to its average volume of 131,819. The stock has a market cap of $267.12 million, a price-to-earnings ratio of -9.03 and a beta of -0.61. The firm’s 50 day simple moving average is $6.68 and its two-hundred day simple moving average is $7.16. The company has a debt-to-equity ratio of 0.08, a current ratio of 16.87 and a quick ratio of 16.87. enGene has a 12 month low of $4.42 and a 12 month high of $18.40.

Wall Street Analysts Forecast Growth

ENGN has been the topic of a number of recent analyst reports. Raymond James started coverage on shares of enGene in a research note on Wednesday, November 27th. They set an “outperform” rating and a $23.00 price target on the stock. HC Wainwright started coverage on enGene in a report on Monday, December 23rd. They issued a “buy” rating and a $25.00 target price on the stock. Citizens Jmp upgraded enGene to a “strong-buy” rating in a research note on Monday, November 18th. JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 price objective on shares of enGene in a research note on Monday, December 23rd. Finally, UBS Group lowered shares of enGene from a “buy” rating to a “neutral” rating and cut their price target for the company from $34.00 to $7.00 in a report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $25.89.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.